Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBrief Communications

The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST

Katja Pinker, Christopher C. Riedl, Leonard Ong, Maxine Jochelson, Gary A. Ulaner, Heather McArthur, Maura Dickler, Mithad Gönen and Wolfgang A. Weber
Journal of Nuclear Medicine July 2016, 57 (7) 1102-1104; DOI: https://doi.org/10.2967/jnumed.115.166629
Katja Pinker
1Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
2Division of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher C. Riedl
1Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leonard Ong
1Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maxine Jochelson
3Breast Imaging Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary A. Ulaner
1Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather McArthur
4Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maura Dickler
5Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, New York; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mithad Gönen
6Epidemiology and Biostatistics/Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang A. Weber
1Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 57 no. 7 1102-1104
DOI 
https://doi.org/10.2967/jnumed.115.166629
PubMed 
26985059

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication November 30, 2015
  • Accepted for publication February 17, 2016
  • Published online July 1, 2016.

Article Versions

  • previous version (March 16, 2016 - 08:04).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Katja Pinker1,2,
  2. Christopher C. Riedl1,
  3. Leonard Ong1,
  4. Maxine Jochelson3,
  5. Gary A. Ulaner1,
  6. Heather McArthur4,
  7. Maura Dickler5,
  8. Mithad Gönen6 and
  9. Wolfgang A. Weber1
  1. 1Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
  2. 2Division of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
  3. 3Breast Imaging Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
  4. 4Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
  5. 5Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, New York; and
  6. 6Epidemiology and Biostatistics/Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
  1. For correspondence or reprints contact: Wolfgang A. Weber, Memorial Sloan Kettering Cancer Center, 1275 York Ave., Box 77, New York, NY 10065. E-mail: weberw{at}mskcc.org
View Full Text

Statistics from Altmetric.com

Cited By...

  • 26 Citations
  • 26 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple‐negative breast cancer
    Alice Y. Ho, Christopher A. Barker, Brittany B. Arnold, Simon N. Powell, Zishuo I. Hu, Ayca Gucalp, Lizza Lebron‐Zapata, Hannah Y. Wen, Cindy Kallman, Alessandro D'Agnolo, Zhigang Zhang, Jessica Flynn, Samantha A. Dunn, Heather L. McArthur
    Cancer 2020 126 4
  • Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments
    Katja Pinker, Christopher Riedl, Wolfgang A. Weber
    European Journal of Nuclear Medicine and Molecular Imaging 2017 44 S1
  • PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact?
    Gary A. Ulaner
    American Journal of Roentgenology 2019 213 2
  • A role of FDG-PET/CT for response evaluation in metastatic breast cancer?
    Malene Grubbe Hildebrandt, Mohammad Naghavi-Behzad, Marianne Vogsen
    Seminars in Nuclear Medicine 2022 52 5
  • Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer
    Sofia C. Vaz, John Patrick Pilkington Woll, Fatima Cardoso, David Groheux, Gary J. R. Cook, Gary A. Ulaner, Heather Jacene, Isabel T. Rubio, Jan W. Schoones, Marie-Jeanne Vrancken Peeters, Philip Poortmans, Ritse M. Mann, Stephanie L. Graff, Elizabeth H. Dibble, Lioe-Fee de Geus-Oei
    European Journal of Nuclear Medicine and Molecular Imaging 2024 51 9
  • PERCIST in Perspective
    Joo Hyun O, Richard L. Wahl
    Nuclear Medicine and Molecular Imaging 2018 52 1
  • Role of Fludeoxyglucose in Breast Cancer
    David Groheux
    PET Clinics 2018 13 3
  • 18F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib
    Freba Ahmaddy, Caroline Burgard, Leonie Beyer, Viktoria Florentine Koehler, Peter Bartenstein, Matthias P. Fabritius, Thomas Geyer, Vera Wenter, Harun Ilhan, Christine Spitzweg, Andrei Todica
    Cancers 2021 13 2
  • Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing18F-FDG PET/CT with Conventional CT
    Marianne Vogsen, Frederik Harbo, Nick M. Jakobsen, Henriette J. Nissen, Sara E. Dahlsgaard-Wallenius, Oke Gerke, Jeanette D. Jensen, Jon T. Asmussen, Anne Marie B. Jylling, Poul-Erik Braad, Werner Vach, Marianne Ewertz, Malene G. Hildebrandt
    Journal of Nuclear Medicine 2023 64 3
  • EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program
    Charline Lasnon, Elske Quak, Pierre-Yves Le Roux, Philippe Robin, Michael S. Hofman, David Bourhis, Jason Callahan, David S. Binns, Cédric Desmonts, Pierre-Yves Salaun, Rodney J. Hicks, Nicolas Aide
    EJNMMI Physics 2017 4 1

Article usage

Article usage: March 2016 to April 2025

AbstractFullPdf
Mar 2016379045
Apr 2016176030
May 2016162013
Jun 20168908
Jul 2016781855
Aug 2016143716
Sep 2016113921
Oct 2016741513
Nov 201656713
Dec 201671718
Jan 201777918
Feb 2017451710
Mar 2017582021
Apr 2017461019
May 20174688
Jun 2017371012
Jul 2017391016
Aug 201745108
Sep 20172233
Oct 201732522
Nov 201711825
Dec 20171426
Jan 20182422
Feb 201819826
Mar 201810120
Apr 201812118
May 201811017
Jun 20181339
Jul 20181213
Aug 20181241
Sep 20181126
Oct 20181288
Nov 20181226
Dec 2018555
Jan 20191736
Feb 20192757
Mar 20191029
Apr 20191404
May 20199510
Jun 20191665
Jul 20191477
Aug 2019927
Sep 20191209
Oct 201915812
Nov 20191139
Dec 20191527
Jan 20201538
Feb 20201035
Mar 202016612
Apr 2020844
May 202011712
Jun 202012215
Jul 20201246
Aug 20201536
Sep 20201068
Oct 20201123
Nov 20201088
Dec 2020835
Jan 20214127
Feb 202151016
Mar 202131919
Apr 20211109
May 20212184
Jun 202182310
Jul 202161611
Aug 202141311
Sep 2021436
Oct 202161028
Nov 202111917
Dec 20211147
Jan 202241320
Feb 20225116
Mar 20221109
Apr 20226119
May 20222147
Jun 20222139
Jul 20221152
Aug 2022295
Sep 202231714
Oct 202211215
Nov 2022285
Dec 20226134
Jan 202342010
Feb 2023394
Mar 20237169
Apr 20231167
May 20234108
Jun 202321212
Jul 2023044
Aug 2023247
Sep 2023336
Oct 20235209
Nov 2023244
Dec 20230205
Jan 20243144
Feb 2024263
Mar 20241452
Apr 202431711
May 202447414
Jun 2024103216
Jul 202442014
Aug 2024397
Sep 20248276
Oct 202452415
Nov 20246155
Dec 20241126
Jan 20251710
Feb 20254388
Mar 202552517
Apr 202582218
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 57 (7)
Journal of Nuclear Medicine
Vol. 57, Issue 7
July 1, 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST
Katja Pinker, Christopher C. Riedl, Leonard Ong, Maxine Jochelson, Gary A. Ulaner, Heather McArthur, Maura Dickler, Mithad Gönen, Wolfgang A. Weber
Journal of Nuclear Medicine Jul 2016, 57 (7) 1102-1104; DOI: 10.2967/jnumed.115.166629

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST
Katja Pinker, Christopher C. Riedl, Leonard Ong, Maxine Jochelson, Gary A. Ulaner, Heather McArthur, Maura Dickler, Mithad Gönen, Wolfgang A. Weber
Journal of Nuclear Medicine Jul 2016, 57 (7) 1102-1104; DOI: 10.2967/jnumed.115.166629
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Intraarterial Administration Boosts 177Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients
  • Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
  • Assessment of P-Glycoprotein Transport Activity at the Human Blood–Retina Barrier with (R)‐11C-Verapamil PET
Show more Brief Communications

Similar Articles

Keywords

  • breast cancer
  • 18F-FDG
  • PET
  • PERCIST
  • treatment response
  • prediction
SNMMI

© 2025 SNMMI

Powered by HighWire